By visiting our website or using services provided by Sai Life Sciences, you are accepting the practices described in the Privacy Policy.

We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. By continuing to use this website, you agree that we may store and access cookies on your device.

By clicking “I Accept”, you confirm that you are above the age of 16, that you have read and understood the Cookies Usage and the Privacy Policy, and that you agree to the collection, use and processing of your Personal Information by Sai Life in accordance with said policies.

I accept

Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2024.10.28

Advanced manufacturing facility at Sai Life Sciences, showcasing state-of-the-art equipment and quality control, featured in a blog post about receiving Establishment Inspection Reports (EIRs) from the USFDA.

Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing facilities

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], announced that it has received Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA) for its R&D (Unit II, Hyderabad), and Manufacturing (Unit IV, Bidar) sites in India.

The General Good Manufacturing Practices (GMP) audit was conducted at the integrated R&D campus (Unit II) in April 2024, while the pre-approval inspection (PAI) & General GMP audit was conducted at the Manufacturing facility (Unit IV) in Bidar in June 2024.

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, said, “These audit outcomes reflect Sai Life Sciences’ commitment to maintaining the highest standards of quality and compliance across its R&D and manufacturing facilities. It demonstrates the company’s robust quality systems and its readiness to support the supply of high-quality pharmaceutical products to global markets."

[1] Among listed Indian peers in terms of revenue CAGR as well as EBITDA CAGR over FY22-24.

Share article

More News

2025.05.14

Sai Life Sciences Limited reports robust FY25 results

Revenue grows by 16%; Net Profit up 105% year-on-year Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, ContractResearch, Development and Manufacturing Organization (CRDMO) announced its financial results for the fourth quarter and full year ended March 31, 2025. Financial Performance: Particulars (₹ crores) FY25 FY24 YoY% Q4FY25 Q4FY24 YoY% Revenue from […]
Read more

2025.05.12

Sai Life Sciences wins Gold at CII Southern Region Awards

Sai Life Sciences has been honored with two Gold Awards at the CII Southern Region EHS Excellence Awards 2024, recognizing the company’s exemplary Environment, Health and Safety (EHS) initiatives across its sites in India. While the Integrated R&D Centre, Hyderabad, won Gold Award for EHS Excellence & Sector 2nd Topper in Pharmaceuticals & Healthcare, the […]
Read more

2025.05.02

Sai Life Sciences certified as a Great Place To Work

Sai Life Sciences has been officially certified as a Great Place To Work for 2025–26, a recognition based on feedback from its employees.The certification reflects the company’s culture and the experiences of its people, with positive responses in key areas such as Corporate Brand Image, Competence, Pride, Team, and Leadership Behaviour. Together, these highlight the […]
Read more

2025.05.02

Sai Life Sciences inks agreement with DHL Express to make logistics operations greener

Sai Life Sciences has inked an agreement with DHL Express to adopt its emission-reduced shipping solution — GoGreen Plus (GGP) — for its international logistics operations.To formalize the partnership, Sivaramakrishnan Chittor, CFO, Sai Life Sciences, signed an agreement with R.S. Subramanian, Senior Vice President – South Asia, DHL Express, on April 21, 2025.This collaboration will […]
Read more

2025.04.03

Sai Life Sciences sets up Peptide Research Center in India

Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India.Announcing the launch, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “As the pharmaceutical industry evolves from small molecules to […]
Read more